YDES News & Events

YD Bio Ltd trading halted, volatility trading pause

YD Bio highlighted the strategic roadmap shared by CEO Ethan Shen. YD Bio is building a comprehensive ecosystem that synchronizes diagnostic intelligence with advanced therapeutic execution. By integrating cancer detection technologies with late-stage dendritic cell immunotherapy programs, the company aims to create a cohesive cycle of data-informed therapy and disciplined clinical translation. YD Bio Ltd is connecting early cancer and aging detection programs with late-stage dendritic cell immunotherapy. By using diagnostic data to monitor and evaluate therapeutic responses, the Company creates a feedback loop that informs and accelerates clinical decision-making. By serving as an Official U.S. Agent for FDA submissions and successfully completing its first FDA IND filing, the company has embedded itself directly into the regulatory process. The company is targeting a conditional clinical pathway milestone in Taiwan by 2027 for its glioblastoma dendritic cell therapy.

YD Bio announced that its subsidiary YD Bio USA entered into a Master Strategic Alliance Agreement with YC Biotech on February 24, 2026. This partnership represents a pivotal advancement in the Company's mission, establishing YD Bio USA as the official strategic hub and exclusive U.S. Agent for regulatory applications to the U.S. Food and Drug Administration for YC Biotech's Contract Research Organization, CRO, clients in Asia. Under the terms of the Agreement, YD Bio USA will serve as YC Biotech's exclusive U.S. Agent and formal liaison with the FDA. In this role, YD Bio USA will manage official communications and correspondence with the FDA, represent sponsors in pre-IND and other formal regulatory meetings, provide high-level U.S. regulatory pathway strategies and positioning advice, and serve as compliance risk advisor. YD Bio USA will also coordinate FDA inspection readiness efforts to facilitate compliance with applicable U.S. regulatory requirements.